MedTrace Logo

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Conditions

  • Metastatic Non-small Cell Lung Cancer
  • Locally Advanced Urothelial Cancer
  • Metastatic Urothelial Cancer
  • Unresectable Melanoma
  • Metastatic Melanoma
  • Locally Advanced Renal Cell Carcinoma
  • Metastatic Clear-Cell Renal Cell Carcinoma

Interventions

DRUG

Retifanlimab

Retifanlimab administered intravenously at 500 mg every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Mark Cornfeld, MD · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-09
Primary Completion
2021-04-15
Completion
2022-06-28
FDA Drug
Yes

Countries

  • United States
  • Austria
  • France
  • Hungary
  • Italy
  • Poland
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679767 on ClinicalTrials.gov